A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus (NCT06575426)
A Phase I/IIa, Single Site, Open-Label, Ascending Dose Study to Evaluate the Safety and Efficacy of OPF-310 [Encapsulated Porcine Islet Cells for Xenotransplantation] in Subjects With Type 1 Diabetes Mellitus
🩺 Plain-English Summary (8th-Grade Level)
This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the recommended Phase 2 dose (RP2D) in adult subjects with unstable Type 1 Diabetes Mellitus (T1DM) and a level 3 (severe) hypoglycemic episode at least three times within the 1 year prior to enrollment despite treatment with a closed loop system (CLS) for at least 6 months.
Who can join: Review the eligibility criteria below.
Location: University of Illinois Hospital & Health Sciences System — Chicago, Illinois
Age range: 35 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Illinois Hospital & Health Sciences System — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (847) 500-9204
Email: opf-310_autoreply@opf-america.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Mellitus, Type 1
- Testing an Integrated Care Model Trial — Atlanta, Georgia
- Safety of ENC-201-CED ENCRT — Toronto, Ontario
- Teplizumab in Pediatric Stage 2 Type 1 Diabetes — San Francisco, California
- Allogenic Islet Cell Transplantation — Chicago, Illinois
- Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells — Charleston, South Carolina
- Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes — Stanford, California
Explore by condition: All Diabetes Mellitus, Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.